LBF16000PG01: Difference between revisions

No edit summary
No edit summary
 
(17 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Lipid/Header}}
{{Hierarchy|{{PAGENAME}}}}
{{Hierarchy|{{PAGENAME}}}}


Line 4: Line 6:
|LipidBank=XPR1421
|LipidBank=XPR1421
|LipidMaps=LMFA03010136
|LipidMaps=LMFA03010136
|SysName=8-[2(R)-(2-Carboxyethyl)-5(R)-hydroxy-3-oxocyclopentan-1(R)-yl]-6-oxooctanoic acid
|SysName=8- [ 2R- (2-Carboxyethyl) -5R-hydroxy-3-oxocyclopentan- 1R-yl ] -6-oxooctanoic acid
|Common Name=&&8-[2(R)-(2-Carboxyethyl)-5(R)-hydroxy-3-oxocyclopentan-1(R)-yl]-6-oxooctanoic acid&&
|Common Name=&&8- [ 2 (R) - (2-Carboxyethyl) -5 (R) -hydroxy-3-oxocyclopentan-1 (R) -yl ] -6-oxooctanoic acid&&
|Solubility=ETHYL ACETATE [[Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177}}]]
|Solubility=ETHYL ACETATE [[Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177}}]]
|Mass Spectra=DIMETHYL ESTER DI-O-METHYLOXIME TMS ETHER DERIVATIVE ; m/e 486, 455, 369, 365, 355, 286, 279, 268, 265, 196, 115 [[Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177}}]]
|Mass Spectra=DIMETHYL ESTER DI-O-METHYLOXIME TMS ETHER DERIVATIVE ; m/e 486, 455, 369, 365, 355, 286, 279, 268, 265, 196, 115 [[Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,2177}}]]
|Source=When prostaglandin E2 or E1 was administered intravenously to man, 7 alpha -hydroxy-5,11-diketo-tetranor-prosta-1,16-dioic acid was found as a major urinary metabolite (PGE-MUM) [[Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713}}]].
|Chemical Synthesis=
|Metabolism=
|Symbol=PGE-MUM
}}
}}
{{Lipid/Footer}}

Latest revision as of 06:38, 21 October 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



8- [ 2 (R) - (2-Carboxyethyl) -5 (R) -hydroxy-3-oxocyclopentan-1 (R) -yl ] -6-oxooctanoic acid
LBF16000PG01.png
Structural Information
8- [ 2R- (2-Carboxyethyl) -5R-hydroxy-3-oxocyclopentan- 1R-yl ] -6-oxooctanoic acid
  • 8- [ 2 (R) - (2-Carboxyethyl) -5 (R) -hydroxy-3-oxocyclopentan-1 (R) -yl ] -6-oxooctanoic acid
PGE-MUM
Formula C16H24O7
Exact Mass 328.152203122
Average Mass 328.35756000000003
SMILES OC(=O)CCCCC(=O)CC[C@@H]([C@H](O)1)[C@@H](CCC(O)=O)C(=O)C1
Physicochemical Information
ETHYL ACETATE HambergMet al.
When prostaglandin E2 or E1 was administered intravenously to man, 7 alpha -hydroxy-5,11-diketo-tetranor-prosta-1,16-dioic acid was found as a major urinary metabolite (PGE-MUM) Hamberg_M et al..
Spectral Information
Mass Spectra DIMETHYL ESTER DI-O-METHYLOXIME TMS ETHER DERIVATIVE ; m/e 486, 455, 369, 365, 355, 286, 279, 268, 265, 196, 115 HambergMet al.
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF16000PG01 See above. Hamberg_M et al. 1969
n.a. LBF16000PG01 See above. Hamberg_M et al. 1971